Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy
2023; Mary Ann Liebert, Inc.; Volume: 33; Issue: 9 Linguagem: Inglês
10.1089/thy.2022.0707
ISSN1557-9077
AutoresJonathan Wadsley, Gemma Ainsworth, Amy Beth Coulson, Kate Garcez, Laura Moss, Kate Newbold, Kate Farnell, Jayne Swain, Helen Howard, Matthew Beasley, Andrew Weaver, Katie Wood, J. L. Marshall, Matthew Griffin, A. Pascoe, Yong Du, J. Taprogge, Glenn Flux, Sarah Brown,
Tópico(s)Meningioma and schwannoma management
ResumoThyroidVol. 33, No. 9 Research LettersResults of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine TherapyJon Wadsley, Gemma Ainsworth, Amy Beth Coulson, Kate Garcez, Laura Moss, Kate Newbold, Kate Farnell, Jayne Swain, Helen Howard, Matthew Beasley, Andrew Weaver, Katie Wood, Jennifer Marshall, Matthew Griffin, Abigail Pascoe, Yong Du, Jan Taprogge, Glenn Flux, and Sarah BrownJon WadsleyAddress correspondence to: Jon Wadsley, FRCR, Weston Park Hospital, S10 2SJ Sheffield, United Kingdom E-mail Address: [email protected]Weston Park Hospital, Sheffield, United Kingdom.Search for more papers by this author, Gemma AinsworthLeeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.Search for more papers by this author, Amy Beth CoulsonLeeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.Search for more papers by this author, Kate GarcezChristie NHS Foundation Trust, Manchester, United Kingdom.Search for more papers by this author, Laura MossVelindre Cancer Centre, Cardiff, United Kingdom.Search for more papers by this author, Kate NewboldThe Royal Marsden NHS Foundation Trust, London, United Kingdom.Search for more papers by this author, Kate FarnellButterfly Thyroid Cancer Trust, NCCC Freeman Hospital, Newcastle, United Kingdom.Search for more papers by this author, Jayne SwainLeeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.Search for more papers by this author, Helen HowardLeeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.Search for more papers by this author, Matthew BeasleyBristol Haematology and Oncology Centre, Bristol, United Kingdom.Search for more papers by this author, Andrew WeaverOxford Churchill Hospital, Oxford, United Kingdom.Search for more papers by this author, Katie WoodRoyal Surrey County Hospital, Guildford, United Kingdom.Search for more papers by this author, Jennifer MarshallUniversity Hospital Southampton, Southampton, United Kingdom.Search for more papers by this author, Matthew GriffinNottingham University Hospitals NHS Trust, Nottingham, United Kingdom.Search for more papers by this author, Abigail PascoeNottingham University Hospitals NHS Trust, Nottingham, United Kingdom.Search for more papers by this author, Yong DuThe Royal Marsden NHS Foundation Trust, London, United Kingdom.Search for more papers by this author, Jan Taproggehttps://orcid.org/0000-0001-9947-2857Joint Department of Physics, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.The Institute of Cancer Research, London, United Kingdom.Search for more papers by this author, Glenn FluxJoint Department of Physics, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.The Institute of Cancer Research, London, United Kingdom.Search for more papers by this author, and Sarah BrownSarah Brown, PhD, Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds LS2 9JT, United Kingdom E-mail Address: [email protected]https://orcid.org/0000-0002-7975-7537Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom.Search for more papers by this authorPublished Online:13 Sep 2023https://doi.org/10.1089/thy.2022.0707AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 33Issue 9Sep 2023 InformationCopyright 2023, Mary Ann Liebert, Inc., publishersTo cite this article:Jon Wadsley, Gemma Ainsworth, Amy Beth Coulson, Kate Garcez, Laura Moss, Kate Newbold, Kate Farnell, Jayne Swain, Helen Howard, Matthew Beasley, Andrew Weaver, Katie Wood, Jennifer Marshall, Matthew Griffin, Abigail Pascoe, Yong Du, Jan Taprogge, Glenn Flux, and Sarah Brown.Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.Thyroid®.Sep 2023.1119-1123.http://doi.org/10.1089/thy.2022.0707Published in Volume: 33 Issue 9: September 13, 2023Online Ahead of Print:September 1, 2023Online Ahead of Editing: August 11, 2023PDF download
Referência(s)